Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas increased his stake during 2025, adding 3,398,055 shares year-to-date, including 301,101 shares bought between Nov 19–28, 2025. Following these purchases, his total ownership stands at 6,459,985 shares. The company noted record-breaking Q3 2025 results across revenue, gross profit, and gross margins but said its valuation remains under pressure. The release directs investors to Form 4 filings for transaction-level details such as ownership form, dates, amounts, and prices.

Cosmos Health (NASDAQ:COSM) reported record Q3 2025 results with revenue up 38% to $17.11M, gross profit up 116% to $2.60M, and a record gross margin of 15.21%. Adjusted EBITDA improved 74% to ($0.19M) and adjusted EPS narrowed to ($0.02) in Q3; nine-month adjusted EPS turned positive to $0.02. Cash rose sharply to $4.63M from $0.66M at June 30, 2025. The company secured a $300M digital financing facility and began Ethereum purchases, expanded U.S. operations for Sky Premium Life, and signed a contract manufacturing deal for MYCOFAGYL. Operating loss and GAAP net loss widened due to non-cash derivative and convertible-note charges.

Cosmos Health (NASDAQ:COSM) announced a new nanotechnology R&D program launched on October 31, 2025 to develop plant-based extract-loaded phytosomes for dietary supplements.

The program builds on the company’s CCX Hydrogel platform and aims to improve absorption, stability, and bioactivity of phytochemicals using a sustainable, solvent-free process suitable for nutraceutical formulation. Company leaders described the work as an effort to deliver next-generation, scientifically driven supplements with validated functional performance.

Cosmos Health (NASDAQ:COSM) announced on October 21, 2025 that it purchased an additional $200,000 of Ethereum (ETH), bringing its total ETH holdings to $2 million.

The acquisition was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify and strengthen its long‑term asset base through targeted digital asset investments.

Cosmos Health (NASDAQ:COSM) announced on October 16, 2025 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. Nasdaq confirmed the company’s closing bid price was at or above $1.00 for 18 consecutive business days from September 22, 2025 to October 15, 2025. As a result, Nasdaq has closed the matter and the Company is now in compliance with the listing rule. The company said this compliance was achieved organically and attributed to execution of strategic initiatives and strengthening fundamentals, and reiterated focus on shareholder value and its digital asset strategy.

Cosmos Health (NASDAQ:COSM) announced on October 13, 2025 that it purchased an additional $300,000 of Ethereum (ETH), bringing its total ETH holdings to $1.8 million. The purchase was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify holdings via strategic digital asset investments. Management reiterated commitment to continue the acquisition program under the financing facility.

Cosmos Health (NASDAQ:COSM) announced on October 10, 2025 that it purchased an additional $500,000 of Ethereum (ETH), bringing its total ETH holdings to $1.5 million. The purchase was executed under the company’s existing $300 million digital assets facility as part of a balance-sheet diversification strategy and to explore blockchain-enabled healthcare solutions. Management reiterated intent to continue using the financing facility and described digital assets as both long-term investments and potential enablers of decentralized healthcare applications.

Cosmos Health (NASDAQ:COSM) announced that subsidiary SkyPharm S.A. signed an exclusive distribution agreement dated September 28, 2025 with Diyar United to market and sell Sky Premium Life® nutraceuticals in Kuwait. Diyar United will manage registration, promotion, logistics and distribution for formulations including collagen, hyaluronic acid, vitamins B/C/D3+K2, magnesium, zinc, turmeric, maca, rhodiola, multivitamins and hair/skin/nail blends. Cosmos secured an initial purchase order of over 65,000 units, with further orders expected as the sales pipeline develops. The PR cites Kuwait’s supplements market at $1.16B in 2024, projected to $1.68B by 2030 (CAGR ~6.3%).

Cosmos Health (NASDAQ:COSM) CEO Greg Siokas outlined the company's transformation into a global healthcare powerhouse, highlighting several major developments. The company secured a $300 million digital financing facility, with 72.5% allocated to building a digital treasury reserve in cryptocurrencies and the remainder for working capital and growth initiatives.

Key achievements include: expansion of U.S. manufacturing operations through NOOR Collagen partnership, significant growth of Sky Premium Life brand across multiple international markets, and record performance from CosmoFarm wholesale division with $43 million revenue in first 10 months of 2024. The company's Cana Laboratories secured major contracts, including a 10-year agreement for 8 million packs with Provident Pharmaceuticals.

The company advanced its R&D pipeline, particularly with obesity treatment CCX0722, and expanded its portfolio through acquisitions and partnerships in pharmaceuticals and diagnostics.